FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1635320150> ?p ?o ?g. }

• W1635320150 endingPage "12413" @default.
• W1635320150 startingPage "12410" @default.
• W1635320150 abstract "Abstract Cysteine farnesylation of the ras oncogene product, p21ras, on its carboxyl-terminal CA1A2X box (C = cysteine, A = aliphatic, and X = methionine or serine) is required for its transforming activity. p21ras farnesyltransferase (FTase), the enzyme responsible or this important posttranslational modification can be inhibited by simple CA1A2X peptides. We have synthesized a family of CA1A2X peptidomimetics where the central 2 aliphatic amino acids are replaced by a variety of spacer groups with different shapes and conformational characteristics to investigate the structural requirements of these inhibitors. The biological activities of CA1A2X peptidomimetics, where the dipeptide A1A2 is replaced by 3- or 4-aminomethylbenzoic acid (AMBA) and 3- or 4-aminobenzoic acid (ABA), are evaluated in a p21ras FTase inhibitory assay. Peptidomimetics Cys-4-ABA-Met and Cys-3-AMBA-Met contain spacers that provide good distance correspondence of the carboxylate and ammonium separation with that of the parent KB p21ras tetrapeptide, Cys-Val-Ile-Met, and are as potent FTase inhibitors (IC50 values of 50 and 100 nM, respectively). In contrast, replacing the central dipeptide with 4-AMBA reduced FTase inhibitory activity by 17-fold whereas replacement by 3-ABA reduces inhibitory activity of the peptidomimetics by 43-fold. Cys-4-ABA-Met (IC50 = 50 nM) is 128 times more potent as a p21ras FTase inhibitor than Cys-3-ABA-Met (IC50 = 6400 nM), yet these two peptidomimetics differ only in the substitution pattern around the phenyl ring. These results coupled with computer modeling studies demonstrate that the interaction between FTase and the peptidomimetics requires precise structural and conformational characteristics; in particular, correct positioning of the Cys and Met must be respected. Furthermore, Cys-3-AMBA-Met and Cys-4-ABA-Met are true inhibitors of p21ras FTase since they are not farnesylated by this enzyme, in contrast to Cys-Val-Ile-Met, which inhibits the enzyme by acting as alternative substrate. Computer modeling studies of the potent FTase inhibitor Cys-4-ABA-Met show that a folded conformation, where the thiol and carboxylate groups are close, is not possible. Therefore a beta-turn conformation that would result in the simultaneous coordination of the Cys-thiol and Met-carboxylate to zinc ion is not important for inhibition of p21ras FTase, as previously suggested." @default.
• W1635320150 created "2016-06-24" @default.
• W1635320150 creator A5014966483 @default.
• W1635320150 creator A5021167157 @default.
• W1635320150 creator A5022444184 @default.
• W1635320150 creator A5044268981 @default.
• W1635320150 creator A5051567432 @default.
• W1635320150 creator A5056350826 @default.
• W1635320150 creator A5068626161 @default.
• W1635320150 date "1994-04-01" @default.
• W1635320150 modified "2023-10-15" @default.
• W1635320150 title "Design and structural requirements of potent peptidomimetic inhibitors of p21ras farnesyltransferase." @default.
• W1635320150 cites W1507061989 @default.
• W1635320150 cites W1544277307 @default.
• W1635320150 cites W1557478309 @default.
• W1635320150 cites W1572144604 @default.
• W1635320150 cites W1607745865 @default.
• W1635320150 cites W1833275968 @default.
• W1635320150 cites W1970030465 @default.
• W1635320150 cites W1974376322 @default.
• W1635320150 cites W1985666310 @default.
• W1635320150 cites W1993418815 @default.
• W1635320150 cites W2010207338 @default.
• W1635320150 cites W2010488494 @default.
• W1635320150 cites W2035363409 @default.
• W1635320150 cites W2036082581 @default.
• W1635320150 cites W2037480365 @default.
• W1635320150 cites W2058333572 @default.
• W1635320150 cites W2060264934 @default.
• W1635320150 cites W2061209225 @default.
• W1635320150 cites W207418012 @default.
• W1635320150 cites W2086589373 @default.
• W1635320150 cites W2089906643 @default.
• W1635320150 cites W2092061547 @default.
• W1635320150 cites W2098806204 @default.
• W1635320150 cites W2133362776 @default.
• W1635320150 cites W2149077527 @default.
• W1635320150 cites W4232777855 @default.
• W1635320150 doi "https://doi.org/10.1016/s0021-9258(18)99888-1" @default.
• W1635320150 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8175645" @default.
• W1635320150 hasPublicationYear "1994" @default.
• W1635320150 type Work @default.
• W1635320150 sameAs 1635320150 @default.
• W1635320150 citedByCount "108" @default.
• W1635320150 countsByYear W16353201502012 @default.
• W1635320150 countsByYear W16353201502013 @default.
• W1635320150 countsByYear W16353201502014 @default.
• W1635320150 countsByYear W16353201502015 @default.
• W1635320150 countsByYear W16353201502016 @default.
• W1635320150 countsByYear W16353201502020 @default.
• W1635320150 countsByYear W16353201502021 @default.
• W1635320150 crossrefType "journal-article" @default.
• W1635320150 hasAuthorship W1635320150A5014966483 @default.
• W1635320150 hasAuthorship W1635320150A5021167157 @default.
• W1635320150 hasAuthorship W1635320150A5022444184 @default.
• W1635320150 hasAuthorship W1635320150A5044268981 @default.
• W1635320150 hasAuthorship W1635320150A5051567432 @default.
• W1635320150 hasAuthorship W1635320150A5056350826 @default.
• W1635320150 hasAuthorship W1635320150A5068626161 @default.
• W1635320150 hasBestOaLocation W16353201501 @default.
• W1635320150 hasConcept C124790011 @default.
• W1635320150 hasConcept C181199279 @default.
• W1635320150 hasConcept C185592680 @default.
• W1635320150 hasConcept C2777827897 @default.
• W1635320150 hasConcept C2778396349 @default.
• W1635320150 hasConcept C2779281246 @default.
• W1635320150 hasConcept C2779716203 @default.
• W1635320150 hasConcept C55493867 @default.
• W1635320150 hasConcept C57790582 @default.
• W1635320150 hasConcept C70721500 @default.
• W1635320150 hasConcept C71924100 @default.
• W1635320150 hasConcept C86803240 @default.
• W1635320150 hasConcept C98274493 @default.
• W1635320150 hasConceptScore W1635320150C124790011 @default.
• W1635320150 hasConceptScore W1635320150C181199279 @default.
• W1635320150 hasConceptScore W1635320150C185592680 @default.
• W1635320150 hasConceptScore W1635320150C2777827897 @default.
• W1635320150 hasConceptScore W1635320150C2778396349 @default.
• W1635320150 hasConceptScore W1635320150C2779281246 @default.
• W1635320150 hasConceptScore W1635320150C2779716203 @default.
• W1635320150 hasConceptScore W1635320150C55493867 @default.
• W1635320150 hasConceptScore W1635320150C57790582 @default.
• W1635320150 hasConceptScore W1635320150C70721500 @default.
• W1635320150 hasConceptScore W1635320150C71924100 @default.
• W1635320150 hasConceptScore W1635320150C86803240 @default.
• W1635320150 hasConceptScore W1635320150C98274493 @default.
• W1635320150 hasIssue "17" @default.
• W1635320150 hasLocation W16353201501 @default.
• W1635320150 hasOpenAccess W1635320150 @default.
• W1635320150 hasPrimaryLocation W16353201501 @default.
• W1635320150 hasRelatedWork W1964186173 @default.
• W1635320150 hasRelatedWork W1984485872 @default.
• W1635320150 hasRelatedWork W2038634407 @default.
• W1635320150 hasRelatedWork W2048406231 @default.
• W1635320150 hasRelatedWork W2073826564 @default.
• W1635320150 hasRelatedWork W2103221476 @default.
• W1635320150 hasRelatedWork W2126918368 @default.
• W1635320150 hasRelatedWork W2174826339 @default.

• next